

12<sup>th</sup> December, 2023

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai -400001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G.Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

---

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

- The USFDA conducted a Pre-Approval Inspection (PAI) at the Company's Oral-Oncology manufacturing facility situated in Bileshwarpura, Gujarat from 05-Dec-23 to 11-Dec-23.
- At the end of the inspection, the Company was issued a Form 483 with 5 procedural observations. There was no observation related to data integrity reported. We will respond to the USFDA within the prescribed timeframe and will work in close collaboration with the agency to address the observations at the earliest possible time.

We will keep the stock exchanges informed of any material development relating to the above in the future.

Please take the information on record.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI  
COMPANY SECRETARY

---

**TORRENT PHARMACEUTICALS LIMITED**

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,

[www.torrentpharma.com](http://www.torrentpharma.com), Email Id: [investorservices@torrentpharma.com](mailto:investorservices@torrentpharma.com)